July 15, 2024
Epidermolysis Bullosa Market

Increased R&D Spending to Fuel Growth of the Epidermolysis Bullosa Market

The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3813.38 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Epidermolysis bullosa (EB) is a group of rare inherited connective tissue disorders that cause easy or abnormal blistering of the skin and mucous membranes. There are various types of EB that are distinguished based on the level within the skin or mucous membranes where blisters occur. EB affect both children and adults and can range from relatively mild to severe. The market is driven by increasing R&D spending by key companies to develop novel treatments for EB along with government support for orphan drug development. Existing treatment options are limited to managing symptoms and improving wound healing through dressings. Development of novel gene and cell therapies hold promise to potentially provide curative options in future.

Market key trends:

One of the key trends in the EB market is increasing pipeline drugs in clinical trials. Companies are investing in gene and cell therapies to provide cure for various EB types. For instance, Krystal Biotech is evaluating KB105, an HSV-1-based gene therapeutic, in a Phase I/II clinical trial for dystrophic EB. Another company Abeona Therapeutics is developing EB-101, an autologous, gene corrected cell therapy using a retroviral vector for recessive dystrophic EB in Phase III trials. Such advances could transform the treatment landscape in coming years.

Porter’s Analysis

Threat of new entrants: The threat of entry is low in this niche market owing to high R&D costs required to develop new products and therapies for rare diseases like Epidermolysis Bullosa. Existing players have well established distribution and production networks.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are only a few approved therapies available currently. However, the serious nature of the disease increases patient dependence on available treatments.
Bargaining power of suppliers: A few pharma and biotech companies have proprietary technologies for EB treatments giving them some power over manufacturers. Suppliers can impact costs if multiple molecules are required from the same source.
Threat of new substitutes: Currently there are limited treatment options for EB making prospects of substitutes low. However, new gene therapies, cell therapies and strategic partnerships can introduce novel alternatives.
Competitive rivalry: Competition is intensifying as major players focus on advancing their clinical pipelines and obtaining regulatory approvals. Partnerships and M&A activity also influence competitive dynamics in this domain.

Key Takeaways

The Global Epidermolysis Bullosa Market Size is expected to witness high growth, exhibiting 11% CAGR over the forecast period, due to increasing research into novel therapies.

Regional analysis: North America currently dominates the EB market owing to supportive regulatory environment and availability of advanced healthcare facilities. Asia Pacific is expected to be the fastest growing market propelled by rising EB incidence, growing medical tourism and improving access to treatments.

Key players: Key players operating in the EB market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma recently received FDA approval for Oleogel-S10, a topical therapy for EB patients. Krystal Biotech is also progressing rapidly with its gene therapy candidate.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it